Investor Presentaiton
126
Investor presentation Full year 2022
Rest of World at a glance
Million
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Rest of World
Novo Nordisk reported sales
300
250
18%
200
150
286
40
227
100
187
50
DKK
21%
billion
Full year 2022
Sales
(mDKK)
Growth²
Total GLP-13
7,604
78%
88
80
80%
Long-acting insulin4
2,610
11%
Premix insulin5
2,489
5%
60
Fast-acting insulin
2,428
11%
60
34%1
GLP-1
60%
Human insulin
Insulin
2,713
-4%
2%1
Total insulin
10,240
5%
40
40%
Other Diabetes care?
530
11%
Diabetes care
18,374
26%
5%1
OAD
20
20
20%
Obesity care8
2,138
61%
Diabetes & Obesity
20,512
29%
0
2021
0
0%
care
2030
2045
Nov
2017
Nov
2022
Population with diabetes
Diabetes growth rate
Rare disease⁹
Total
4,890
5%
25,402
24%
GLP-1 MS
-Insulin MS
-OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: South & Central America, Southeast Asia
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Nov 2022: Novo Nordisk 58%, Sanofi
24% and Eli Lilly 13%; Competitor GLP-1 value market shares, as of Nov 2022: Novo
Nordisk 73%, Eli Lilly 26% and AstraZeneca 0.4%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, Nov 2022 value
figures
2 At constant exchange rates; 3 Comprises Victoza®, OzempicⓇ and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ; 5 Comprises NovoMixⓇ and
RyzodegⓇ 6 Comprises NovoRapidⓇ and FiaspⓇ:7 Comprises NovoNormⓇ and
needles;; 8 Comprises SaxendaⓇ: 9 Comprises primarily Esperoct®, Refixia®
,NovoSeven®, Novo Eight® and Norditropin®View entire presentation